Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Alembic Pharmaceuticals receives USFDA tentative approval for Larotrectinib Capsules
Alembic Pharmaceuticals has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of Bayer Healthcare Pharmaceuticals Inc. (Bayer).
Amber Forms Electronics Subsidiary ILJIN Technologies | Alembic Pharma Invests in Canada Venture | Top Buzzing Stocks Today - Equitymaster
Amber Forms Electronics Subsidiary ILJIN Technologies | Alembic Pharma Invests in Canada Venture | Top Buzzing Stocks TodayEquitymaster
Amber Forms Electronics Subsidiary ILJIN Technologies | Alembic Pharma Invests in Canada Venture | Top Buzzing Stocks Today - Equitymaster
Amber Forms Electronics Subsidiary ILJIN Technologies | Alembic Pharma Invests in Canada Venture | Top Buzzing Stocks TodayEquitymaster
Stocks to watch: Adani Energy, Hindustan Zinc, Lenskart, ZEE, Alembic Pharma, among key stocks in focus on 8 June - Mint
Stocks to watch: Adani Energy, Hindustan Zinc, Lenskart, ZEE, Alembic Pharma, among key stocks in focus on 8 JuneMint
Alembic Pharma to acquire 45% stake in Canadian venture for pharma market expansion
Alembic Pharmaceuticals enters a Canadian joint venture with a 45% stake as it looks to strengthen its global pharma footprint. Alembic Pharmaceuticals shares closed at ₹742.75 on the NSE, up ₹5.20 or 0.71%.
Alembic Pharma gets USFDA nod for Tourette's Disorder treatment drug
The latest approval adds to Alembic's growing US generics portfolio. The company said it has now received a cumulative 240 ANDA approvals from the USFDA, comprising 221 final approvals and 19 tentative approvals.
Alembic Pharma receives USFDA approval for Haloperidol tablets
Alembic Pharmaceuticals announced that it has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Haloperidol Tablets USP in strengths of 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg.
Alembic Pharmaceuticals receives USFDA approval for Haloperidol Tablets
Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Haloperidol Tablets, USP, 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg.
Alembic Pharmaceuticals to attend Trinity India 2026 conference - scanx.trade
Alembic Pharmaceuticals to attend Trinity India 2026 conferencescanx.trade
Alembic gets USFDA nod for generic levothyroxine sodium tablets
Alembic Pharmaceuticals has secured final approval from the US health regulator for its generic levothyroxine sodium tablets. This medication is used as a replacement therapy for hypothyroidism. The approval covers multiple strengths of the tablets. This development is significant for patients seeking affordable treatment options. The market for these tablets is substantial.
Alembic Pharma gets USFDA nod for thyroid disorder and cancer treatment drug
Alembic Pharmaceuticals gets USFDA nod for Levothyroxine Sodium Tablets, used as replacement therapy for congenital or acquired hypothyroidism and are also indicated as an adjunct treatment in certain thyroid cancer cases. This boosts Alembic Pharma's ANDA tally to 239.
Alembic Pharmaceuticals receives USFDA approval for Levothyroxine Sodium Tablets
Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Levothyroxine Sodium Tablets USP, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg and 300 mcg.